Steris (STE) Cash & Equivalents (2017 - 2026)

Steris' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $439.6 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 156.03% year-over-year to $439.6 million in Q1 2026; TTM through Mar 2026 was $439.6 million, a 156.03% increase from a year earlier, with the FY2026 full-year figure at $439.6 million, up 156.03% from the prior year.
• Cash & Equivalents grew to $439.6 million in Q1 2026 per STE's latest filing, from $423.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $439.6 million in Q1 2026 and bottomed at $155.2 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $213.8 million (2023), against an average of $257.4 million.
• Across the five-year window, Cash & Equivalents plunged 40.85% in 2022 and jumped 173.04% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $259.4 million in 2022, then dropped by 24.59% to $195.6 million in 2023, then dropped by 20.66% to $155.2 million in 2024, then surged by 173.04% to $423.7 million in 2025, then climbed by 3.75% to $439.6 million in 2026.
• Per Business Quant, the three latest STE Cash & Equivalents figures stand at $439.6 million (Q1 2026), $423.7 million (Q4 2025), and $319.2 million (Q3 2025).